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CARBAPENEM-RESISTANT 
ACINETOBACTER 
THREAT LEVEL URGENT
8,500
Estimated cases 
in hospitalized 
patients in 2017 
700
Estimated 
deaths in 2017 
$281M
Estimated attributable 
healthcare costs in 2017
Acinetobacter bacteria can survive a long time on surfaces. Nearly all carbapenem-resistant Acinetobacter 
infections happen in patients who recently received care in a healthcare facility. 
WHAT YOU NEED TO KNOW
 ■ Carbapenem-resistant Acinetobacter cause pneumonia 
and wound, bloodstream, and urinary tract infections. 
These infections tend to occur in patients in intensive 
care units.
 ■ Carbapenem-resistant Acinetobacter can carry  
mobile genetic elements that are easily shared  
between bacteria. Some can make a carbapenemase 
enzyme, which makes carbapenem antibiotics 
ineffective and rapidly spreads resistance that  
destroys these important drugs.
 ■ Some Acinetobacter are resistant to nearly all 
antibiotics and few new drugs are in development.
CASES OVER TIME
Continued infection control and appropriate antibiotic use 
are important to maintain decreases in carbapenem-resistant 
Acinetobacter infections.
CARBAPENEM-RESISTANT ACINETOBACTER 
A THREAT IN HEALTHCARE 
Acinetobacter is a challenging threat to hospitalized 
patients because it frequently contaminates healthcare 
facility surfaces and shared medical equipment. If not 
addressed through infection control measures, including 
rigorous cleaning and disinfection, outbreaks  
in hospitals and nursing homes can occur.
Acinetobacter is already resistant to many antibiotics. 
Resistance to carbapenems further reduces patient 
treatment options. Overall rates of carbapenem-
resistant Acinetobacter cases have decreased; however, 
carbapenem-resistant Acinetobacter that can produce 
carbapenemases, which can spread to other germs 
and amplify the problem of resistance through mobile 
resistance elements (e.g., DNA), appear to be increasing. 
This increase of carbapenemase production threatens  
to reverse decreases of carbapenem-resistant 
Acinetobacter cases. Infections caused by carbapenem-
resistant Acinetobacter baumannii are of particular 
concern because they are frequently difficult to treat with 
available antibiotics.
TREATMENT OVER TIME
Treatment options for infections caused by carbapenem-
resistant Acinetobacter baumannii are extremely limited.  
There are few new drugs in development.
PERCENT OF GERMS THAT TESTED NON-SUSCEPTIBLE 
(NOT SENSITIVE) TO OTHER TYPES OF ANTIBIOTICS
Select  
Antibiotics 2013 2014 2015 2016 2017
Any fluoroquinolone 98% 93% 97% 92% 89%
Any extended-spectrum 
β-lactam 80% 75% 81% 79% 75%
Ampicillin/sulbactam 62% 62% 59% 64% 61%
Trimethoprim/
sulfamethoxazole 84% 74% 81% 77% 66%
Germs refer to isolates (pure samples of germs) from eight of CDC’s Emerging 
Infections Program sites. See Technical Appendix for antibiotic susceptibilities details. 
ONLINE RESOURCES
About Acinetobacter in Healthcare Settings
www.cdc.gov/hai/organisms/acinetobacter.html
Surveillance of Gram-negative Healthcare Infections  
www.cdc.gov/hai/eip/mugsi.html
This fact sheet is part of CDC’s 2019 Antibiotic Resistance Threats Report.  
The full report, including data sources, is available at www.cdc.gov/DrugResistance/Biggest-Threats.html.
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